tiprankstipranks
Advertisement
Advertisement

VERA Stock Latest News

Vera Therapeutics announces alignment with FDA on earlier ORIGIN 3 eGFR analysis
The FlyVera Therapeutics announces alignment with FDA on earlier ORIGIN 3 eGFR analysis
3d ago
VERA
Raymond James sees unique buying opportunity in Vera after FDA alignment
PremiumThe Fly
Raymond James sees unique buying opportunity in Vera after FDA alignment
3d ago
VERA
Vera Therapeutics: Buy Rating Reiterated as Atacicept’s Regulatory Path Advances; $90 Price Target Maintained
PremiumRatings
Vera Therapeutics: Buy Rating Reiterated as Atacicept’s Regulatory Path Advances; $90 Price Target Maintained
3d ago
VERA
Vera Therapeutics Advances Atacicept Approval Path in IgA Nephropathy
PremiumCompany Announcements
Vera Therapeutics Advances Atacicept Approval Path in IgA Nephropathy
3d ago
8K
VERA
Vera Therapeutics Stockholders Back Board, Governance Proposals
PremiumCompany Announcements
Vera Therapeutics Stockholders Back Board, Governance Proposals
10d ago
8K
VERA
Vera Therapeutics price target lowered to $91 from $95 at Evercore ISI
PremiumThe FlyVera Therapeutics price target lowered to $91 from $95 at Evercore ISI
21d ago
VERA
Analyst Reiterates Buy on Vera as Atacicept Progress and Strong Cash Position Support Unchanged $110 Price Target
Premium
Ratings
Analyst Reiterates Buy on Vera as Atacicept Progress and Strong Cash Position Support Unchanged $110 Price Target
24d ago
VERA
Vera Therapeutics: Buy Rating Reiterated on Strong Atacicept Outlook and Launch Readiness; $73 Price Target Maintained
Premium
Ratings
Vera Therapeutics: Buy Rating Reiterated on Strong Atacicept Outlook and Launch Readiness; $73 Price Target Maintained
28d ago
VERA
Vera Therapeutics reports Q1 EPS ($1.69), consensus ($1.37)
PremiumThe Fly
Vera Therapeutics reports Q1 EPS ($1.69), consensus ($1.37)
29d ago
VERA
Vera Therapeutics upgraded to Outperform from Peer Perform at Wolfe Research
PremiumThe Fly
Vera Therapeutics upgraded to Outperform from Peer Perform at Wolfe Research
3M ago
VERA
VRTX
Vertex poses ‘no threat’ to Vera Therapeutics’ atacicept, says BofA
PremiumThe Fly
Vertex poses ‘no threat’ to Vera Therapeutics’ atacicept, says BofA
3M ago
VERA
VRTX
Maintaining the Bull Case on Vera: Atacicept’s Competitive Edge and $2.2B IgAN Peak Sales Upside
PremiumRatings
Maintaining the Bull Case on Vera: Atacicept’s Competitive Edge and $2.2B IgAN Peak Sales Upside
3M ago
VERA
Vera Therapeutics Adds Christopher Hite to Board
PremiumCompany AnnouncementsVera Therapeutics Adds Christopher Hite to Board
3M ago
8K
VERA
Vera Therapeutics appoints Hite to Board of Directors
Premium
The Fly
Vera Therapeutics appoints Hite to Board of Directors
3M ago
VERA
3 Best Stocks With 125%+ Upside Ahead, According to Top Analysts, 3/2/2026
Premium
Market News
3 Best Stocks With 125%+ Upside Ahead, According to Top Analysts, 3/2/2026
3M ago
UPB
VERA
Vera Therapeutics price target raised to $110 from $90 at H.C. Wainwright
PremiumThe Fly
Vera Therapeutics price target raised to $110 from $90 at H.C. Wainwright
3M ago
VERA
Vera Therapeutics: Strong Atacicept Phase 3 Data and Favorable Regulatory, Commercial Setup Support Buy Rating
PremiumRatings
Vera Therapeutics: Strong Atacicept Phase 3 Data and Favorable Regulatory, Commercial Setup Support Buy Rating
3M ago
VERA
Undervalued IgAN Opportunity: Buy Rating on VERA Driven by Atacicept’s Robust ORIGIN 3 Data and Long-Term Kidney Disease Upside
PremiumRatings
Undervalued IgAN Opportunity: Buy Rating on VERA Driven by Atacicept’s Robust ORIGIN 3 Data and Long-Term Kidney Disease Upside
3M ago
VERA
Vera Therapeutics: Buy Rating Backed by Strong Atacicept Data, Robust Cash Runway, and Large IgAN Market Opportunity
PremiumRatings
Vera Therapeutics: Buy Rating Backed by Strong Atacicept Data, Robust Cash Runway, and Large IgAN Market Opportunity
3M ago
VERA
Vera Therapeutics reports FY25 EPS ($4.66), consensus ($4.44)
PremiumThe FlyVera Therapeutics reports FY25 EPS ($4.66), consensus ($4.44)
3M ago
VERA
Vera Therapeutics sees cash runway through atacicept commercial launch
Premium
The Fly
Vera Therapeutics sees cash runway through atacicept commercial launch
3M ago
VERA
Vera Therapeutics appoints Skelton as Chief Commercial Officer
Premium
The Fly
Vera Therapeutics appoints Skelton as Chief Commercial Officer
4M ago
VERA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >